Diaceutics PLC (DXRX) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Diaceutics PLC stock £0.29, price £2.04, upside -85.7%, quality 71 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?No
Quality 50+?Yes
In an uptrend?Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range £0.7450 – £2.05 · fair‑value band £0.2700 – £0.3600 · the £2.04 price screens above the £0.2900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Diaceutics in your weekly email
Every Wednesday you see whether Diaceutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
Show moreShow less
The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories.
It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports.
In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Stock analysis
Diaceutics PLC (DXRX) currently trades at £2.04, while our model-based Fair Value estimate is £0.2900, 85.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of £0.3900 per share, and 0 of the 21 models we run sit above the £2.04 price.
Bear case: the Earnings-Based group reads lowest at £0.0300, and 21 of the 21 models stay below the price. Data coverage for this calculation is low.
Scenario range: £0.2700 (bear) to £0.3600 (bull), the price of £2.04 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Diaceutics PLC reported revenue of £38.4M in FY2025 versus £13.9M in FY2021, a compound +28.9%/yr. Reported net income was £97.0K in FY2025, compounding −35.5%/yr from FY2021.
Key figures
Market cap £172M Micro · P/S ratio 4.12 · Net margin −0.7% · Return on equity −0.7% · Return on assets (EBIT) −1.9% · Operating margin −23.0% · Revenue (TTM) £41.3M · Revenue growth (YoY) +19.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 61% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at −86%, DXRX screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (£0.0200 to £1.29). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear£0.2700Fair Value £0.2900Bull£0.3600
Price £2.04 · Upside -85.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Start year 2020 (pandemic). Over 10 years: +39.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−28.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−28.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−28.7% vs −20.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → −1%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +49.7% a year for the price and +15.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 121 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside−85.7% · Bottom 25%
Profitability
Return on assets0.2% · Below median
Net margin (12 months)−0.7% · Below median
Operating margin (12 months)−23.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)19.9% · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B4.26× · Priciest 25%
P/S (12 months)4.17× · Pricier than median
Price / free cash flow120.9× · Priciest 25%
EV/EBITDA42.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 40
PAST (return on equity)0· sector 11
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Diaceutics PLC Fair Value". https://www.fairvalue-calculator.com/stock/DXRX
Frequently asked questions
Is Diaceutics PLC (DXRX) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of £0.2900 versus a price of £2.04, about −86% upside (overvalued).
What is the fair value of DXRX?
Our model-based fair value for Diaceutics PLC is £0.2900 (as of Oct 28, 2026), built from audited fundamentals. The current price: £2.04.
What is the quality score of DXRX?
Diaceutics PLC has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diaceutics PLC (DXRX)?
Our model-based price target is the fair value of £0.2900 (as of Oct 28, 2026) from 21 valuation models. Cautious scenario £0.2700, optimistic scenario £0.3600. It is a calculation from audited fundamentals, not an analyst target.
What is the Diaceutics PLC stock forecast for 2026?
Our models put fair value at £0.2900, about −86% upside versus a price of £2.04 (overvalued). Cautious scenario £0.2700, optimistic scenario £0.3600. The calculation is refreshed regularly with new filings.
What is the revenue of Diaceutics PLC (DXRX)?
Diaceutics PLC reported trailing-twelve-month revenue of about £41.3M (latest available figure, as of Oct 28, 2026).
What growth is priced into Diaceutics PLC (DXRX)?
For today's price to be fair in a discounted-cash-flow model, Diaceutics PLC would have to grow free cash flow by +53.2 % per year for five years (discount rate 12.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.8 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of DXRX use?
Our models discount Diaceutics PLC at 12.5 %: a base by market capitalisation (micro), damped by beta 0.77, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Diaceutics PLC that is +53.2 % per year a year over ten years, using the same discount rate (12.5 %) and the same formula as our fair value.
How much growth has Diaceutics PLC (DXRX) delivered so far?
Over the past 5 years revenue at Diaceutics PLC grew +24.8 % a year. The price currently implies +53.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Diaceutics PLC (DXRX) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into Diaceutics PLC (+53.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Diaceutics PLC (DXRX)?
The free-cash-flow yield on the price is 0.83 %: that much free cash flow Diaceutics PLC produces per unit of market value. When it exceeds the discount rate of our models (12.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Diaceutics PLC (DXRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diaceutics PLC it is £0.2900 per share (as of Oct 28, 2026), against a price of £2.04. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Diaceutics PLC stock overvalued or undervalued in 2026?
As of Oct 28, 2026, DXRX trades above its calculated fair value: price £2.04, fair value £0.2900, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DXRX?
No. The price is what the market pays today (£2.04); the fair value is what the company's own numbers justify (£0.2900). For Diaceutics PLC the two are £1.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Diaceutics PLC worth?
The market values Diaceutics PLC at about £172M (market capitalisation, as of Oct 28, 2026). Per share that is £2.04; our models calculate a fair value of £0.2900 per share.
What do the bullish and bearish scenarios say about DXRX?
Our models span a range for Diaceutics PLC: cautious scenario £0.2700, base £0.2900, optimistic £0.3600 per share (as of Oct 28, 2026, price £2.04). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Diaceutics PLC (DXRX)?
Balance-sheet figures for Diaceutics PLC (as of Oct 28, 2026): return on equity −0.7%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is DXRX from its 52-week high?
Diaceutics PLC trades at £2.04, at its 52-week high of £2.05 and 61% above the low of £1.27 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2900 is for.
Which stocks are comparable to Diaceutics PLC?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diaceutics PLC stock attractive at the current price?
The data as of Oct 28, 2026: price £2.04, calculated fair value £0.2900 (−86%), Quality Score 71/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DXRX calculated?
We run Diaceutics PLC through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.2900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Diaceutics PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diaceutics PLC (DXRX)?
The closing price on Oct 28, 2026 was £2.04. Our model-based fair value is £0.2900, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diaceutics PLC right now?
A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (£0.3600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Diaceutics PLC
How large is the market capitalisation of Diaceutics PLC (DXRX)?
The market capitalisation of Diaceutics PLC is £172M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diaceutics PLC (DXRX)?
The price-to-sales ratio of Diaceutics PLC is 4.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Diaceutics PLC (DXRX)?
The net margin of Diaceutics PLC is −0.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diaceutics PLC (DXRX)?
The return on equity (ROE) of Diaceutics PLC is −0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diaceutics PLC (DXRX)?
On an EBIT basis the return on assets of Diaceutics PLC is −1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diaceutics PLC (DXRX)?
The operating margin of Diaceutics PLC is −23.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diaceutics PLC (DXRX)?
Revenue at Diaceutics PLC is growing +19.9% versus a year earlier (3y avg +25.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diaceutics PLC (DXRX)?
Earnings per share at Diaceutics PLC are growing +180% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Diaceutics PLC (DXRX) hold?
Diaceutics PLC holds more cash than debt, £6.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Diaceutics PLC in the live analysis
One click puts Diaceutics PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 28, 2026